A transcutaneous energy transformer system (TETS) can provide power to an implanted ventricular assist device (VAD) across an unbroken layer of skin. A TETS includes a subcutaneous secondary coil, which traditionally connects to remote power conditioning circuitry located to avoid eddy current losses and heating that occur in metal near operating TETS coils. Litz wire, used to construct the coil and connect it to that circuitry, efficiently conducts the high frequency alternating current but is bulky and stiff. A novel concept (US Patent No. 6,327,504 B1) packages the secondary coil's output power conditioning circuitry within the unused aperture of the coil while minimizing eddy current losses. The concept allows use of a more flexible cable for its direct current power output. The result is improved reliability, functionality, and efficiency along with decreased implant volume and a thinner, more flexible lead system to interconnect to the VAD. This in turn enhances system versatility by expanding sites available for module implantation. A TETS using this concept has demonstrated efficiency exceeding 80% and peak power outputs of 45 W with good tissue compatibility in the bovine model after a 30 day implant. ASAIO Journal 2004; 50:397-400.
Transcutaneous energy transformer systems (TETS) are desirable when (1) an implanted artificial organ consumes large amounts of power and (2) the artificial organ is intended for long-term implant. Ventricular assist devices (VADs) are an example of such devices, particularly when the indication is destination therapy. In that case, a TETS can provide power to the implanted VAD across an unbroken skin layer, eliminating the possibility of infections associated with percutaneous power lines; however, the advantages of a TETS do not come without cost.
The TETS equipment includes several devices with their attendant volume and weight. Externally, an oscillator circuit converts direct current (DC) to high frequency alternating current (AC). This high frequency AC is applied by low loss Litz wire cabling to a primary coil affixed to the outside of the skin and ideally located coaxially and closely to an implanted secondary coil. The implanted secondary coil inductively couples to the primary coil; high frequency AC in the secondary coil is rectified to DC and is regulated for use by the implanted artificial organ.
The act of transcutaneous energy transmission itself consumes power; 80% DC-DC (input to output) efficiency is considered good. The lost 20% translates into decreased capacity from portable power sources and thus less time on wearable batteries. Power that is not transferred is lost as heat and distributed throughout the TETS. Although the host can tolerate some heat, excessive amounts are undesirable. 1 The efficiency of power transmission itself depends on the close coupling between the external primary coil and the implanted secondary coil. Some axial and radial misalignment can be tolerated, but in the case of devices developed by Thoratec, radial misalignment beyond 50% radial or 3 cm axial leads to decreased transmission efficiency and ultimately loss of power transmission. Additionally, the reliability of the TETS and all its electronic components must be considered compared with the reliability of a straightforward percutaneous cable.
Despite its shortcomings, the case for using a TETS with long-term implanted VADs is compelling. The mounting clinical experience with VADs frequently demonstrates problems associated with the percutaneous driveline. 2 Because of this, the effort to develop an efficient and reliable TETS for use with Thoratec VADs is worthwhile.
The engineering challenge with TETS packaging is related to the intense magnetic field used to transfer power. Application of AC to a coil structure sets up an oriented, time varying magnetic field. In the presence of another appropriately oriented coil, current can be induced to flow in that secondary coil. Similarly, circulating currents can flow in any electrical conductor in the presence of that primary magnetic field. This current depends on the properties of that metal (e.g., size, electrical conductivity, geometry) and can be significant; potentially, the ohmic losses are significant as well.
When work was first began on TETS development in the 1980s, the electrical components themselves constituted an unacceptably large metallic mass. It was because of the potential for these ohmic losses that no attempt was made to package rectification circuitry within the otherwise unused core of the secondary coil. However, new circuit design topologies, devices, and packaging that have emerged recently in the electronics industry have encouraged the reexamination of that position relative to secondary coil design.
The development effort at Thoratec can be traced back as far as 1980, when Thermo Electron Corporation began work on a National Heart Lung Blood Institute contract to develop a TETS. 3 That effort developed hardware for a TETS and subjected it to animal testing in the porcine model. Although it had been intended for use with a fully sealed version of what is now known as the Thoratec HeartMate VE left ventricular assist device (LVAD), expediency dictated that the LVAD instead use a percutaneous cable to proceed toward clinical use. The technology was not abandoned, however, and was subsequently used by other groups. 4 The technology was revisited in 1998 with the intent of redesigning it using the state of the art in power supply design. Although this approach allowed the use of updated circuitry, many of the basic features of the original TETS design were retained, including-• Capacitively tuned primary and secondary coil circuits, • Fundamental frequency of 160 kHz, • Litz wire used for the lowest resistive losses at high fundamental frequency, • Secondary coil geometry unchanged from that previously tested in vivo, and • Regulated DC output voltage.
Use of updated circuitry for the TETS rectifier and voltage regulation circuitry opened an intriguing possibility: the potential to miniaturize this circuitry to the point that it could be located within the annulus of the secondary coil.
The benchmark secondary coil developed back in the early 1980s was 7.1 cm in diameter, 1.87 cm thick, and 114 gms 5 (Figure 1) . Its coil consisted of 16 turns of Litz wire, which also formed the interconnection cable. A moisture barrier was provided by a butyl rubber undercoat and polyurethane over mold. The coil center was functionally unused; it was filled with polyurethane.
With LVAD commercialization using a percutaneous driveline (which also incorporated a volume compensation vent for the pulsatile HeartMate VE), the TETS technology was not actively pursued. It was not until the advent of rotary blood pump type LVADs that the TETS was again revived. By this time, advances in semiconductor technology and packaging enabled the miniaturization and rapid prototyping of circuitry. The TETS concept was reviewed and updated. The resulting early evolution of the secondary coil's rectifier/voltage regulator circuit is shown in Figure 2 . The first implementation of the circuit was on a small square printed circuit board (PCB) 3.8 ϫ 2.7 cm, intended to demonstrate function. The size of this PCB relative to the aperture of the secondary coil offered the po-tential for packaging the two together. Although mindful of the potential for electromagnetically induced heating of the components (eddy current losses), the smaller components used in this circuit relative to those used in the 1980s suggested that such an experiment in packaging was worthwhile. The resultant round PCB (Figure 2, center) was sized to do that. However, testing indicated that with the rectifier/regulator circuit located inside the secondary coil and oriented with the plane of the coil, the eddy current losses were still detectable. However, as the round PCB was rotated through a 90°arc until it was perpendicular to the plane of the operating coil, the eddy current losses decreased. By orienting the PCB such that it minimized the volume of the metallic loop through which the eddy currents could circulate, such losses were minimized. This insight resulted in the two board stack shown in Figure  2 (right), designed to mount perpendicular to the plane of the coil windings. When tested on the bench, there was negligible difference in the input power to the TETS when the rectifier/ regulator PCB was located 10 cm from the coils versus within the aperture of the secondary coil (but perpendicular to the plane of its windings).
A secondary coil with this integrated rectifier/regulator was fabricated and subjected to animal testing. As viewed from its backside in Figure 3 , the coil was first wound with Litz wire and premolded in epoxy. The rectifier/regulator was wired to the coil and the DC output cable and molded within the coil with thermally conductive epoxy. The overall structure was then overmolded with polyurethane.
Materials and Methods
A single, animal experiment was performed to test the reaction of tissue to the integrated secondary coil/rectifier/regulator circuitry. The prototype secondary coil shown in Figure 3 was used. At 7.5 cm diameter and 2 cm thick, this coil was slightly larger, although its overall shape closely approximated that of the original (Figure 1) . A "sham" coil was constructed with solid polyurethane from the same final mold as the functional unit and both were implanted in the same animal.
The bovine model was used in this study, which was conducted in accordance with the Principles of Laboratory Animal Care (National Society for Medical Research) and the Guide for the Care and Use of Laboratory Animals, 6 as well as guidelines determined by the Institutional Animal Care and Use Committee of the University of Pittsburgh. In the bovine model, our implant site was the thoracolumbar region of the back, with the center of the active and sham coils each implanted approximately 25 cm from the spine, one on each side. Coils were implanted in pockets formed in the subcutaneous fascia, overlying the ribs and musculature. Each secondary coil was placed in a Dacron pouch to promote tissue anchoring. The DC output leads from the active and sham coils were tunneled caudally to percutaneous access points near the spine, allowing the active unit to dump power into an external resistive load. Primary coils were sutured in place over the implanted secondary coils. Infection control was effectively provided by prophylactic injection of cefazolin for 5 days postoperatively along with Betadine applied to the percutaneous access site for the duration of the implant.
The implant sites on the animal's back were allowed to heal for 2 weeks before application of power to the active unit. The sham unit remained unpowered but was otherwise maintained in the same manner as the active unit. The active unit delivered a continuous 16 W (at 13.4 V) to a resistive load that was mounted to the calf's back along with the oscillator. The unit was operated in this manner for 30 days before explant. At explant, the only significant finding was a small fibrous area corresponding to an electrolytic capacitor that was inadequately covered by both the heat conducting epoxy and the polyurethane overcoating. The capacitor can be seen as the "blemish" in Figure 3 . Tissue in contact with the unpowered "sham" secondary coil was unremarkable.
Bench testing of the system indicated that, under ideal coil coupling conditions (coaxial alignment and 1 cm coil to coil spacing), 45 W of power could be delivered to the load. It did so at 80% overall efficiency.
Discussion
Although these preliminary results were encouraging, there was room for improvement. Now covered by US Patent 6,327,504 B1, the concept for orienting the rectifier/regulator circuitry within the secondary coil has further advanced toward clinical use. The rectifier/regulator circuitry has been refined such that it fits on a single PCB to further reduce eddy current losses and simplify assembly. In addition the large electrolytic capacitor that was inadequately insulated from the tissue has been eliminated. Figure 4 shows the prototyped hardware, including a custom implantable connector.
By allowing the rectifier/regulator circuitry to be placed within the secondary coil, the overall system enjoys several benefits. The foremost benefit is that the concept allows the use of much smaller and more flexible interconnection cable. This in turn expands the number of potential locations for implant.
The Litz wire required to efficiently conduct high frequency AC consists of individually insulated strands of copper. Litz wire bundles its strands in a nonparallel fashion such that they occupy various positions within the bundle at different points along its length. This results in rather large diameter bundles that also tend to be stiff. The Litz wire in the original TETS was approximately 2.5 mm diameter. The rectified output power from this packaging concept does not require such specialized wire. The resultant DC cable not only is smaller but also can be configured with redundant conductors to improve reliability. Smaller connectors can be used with the smaller DC conductors with their redundancy also improving system reliability.
Currently, the current revision of the TETS is being prepared for in vitro and in vivo testing. versity of Pittsburgh, Pittsburgh, Pennsylvania, for assistance with animal experimentation.
